REVB

Conviction 4HealthcareScan · Thu, Jun 25, 2026

REVB$0.9600-6.80%

ResistanceSupportVol 14

Vol MA14 49.63K

Mar 26Apr 14May 1May 19Jun 8Jun 25

REVELATION BIOSCIENCES, INC.PHARMACEUTICAL PREPARATIONSwww.revbiosciences.com ↗

Price0.9600

Change-6.80%

Gap-2.91%

Rel volume0.77×

Avg volume47.65K

Avg $ vol48.97K

SMA 201.03

SMA 501.07

SMA 2001.18

Price vs 50-10.15%

Price vs 200-18.72%

MA stackbearish

50/200 cross—

Supertrenddown · 1.13

RSI (14)42

MACD hist0.00

MACD crossbull · 3d

Stoch %K / %D6 / 42

ADX (14)17

+DI / −DI18 / 21

RSI divergence—

MACD divergence—

ATR %+6.48%

ADR %5.36%

52w high3.09

52w low0.5230

From 52w high-68.93%

Above 52w low+83.56%

New 52w highNo

SqueezeOn · 6d

Bollinger width16.02%

%B0.07

Donchian pos5.37%

Donchian high1.11

Donchian low0.9515

AVWAP (52w high)1.14

vs AVWAP high-15.71%

AVWAP (52w low)1.31

vs AVWAP low-26.46%

OBV trendDown

Chaikin MF (20)-0.17

Today vs 20d0.77×

Avg vol (14d)49.63K

Avg vol (20d)47.65K

Avg $ vol (20d)48.97K

Market cap3.75M

RS 3m (vs SPY)-20.29%

RS 6m (vs SPY)+7.63%

RS line new highNo

Trend template1/8

Technical rank32.7

1 week-10.28%

1 month-9.43%

3 months-18.64%

6 months+11.90%

1 year+10.34%

YTD+18.05%

P/E-0.42

P/B0.29

P/S—

P/FCF-0.45

EPS-23.95

Div yield—

ROE-68.62%

ROA-59.25%

Debt/Eq—

Current10.02

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth40.73%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-10.36M

Revenue—

Net income-3.01M

Gross profit—

Free cash flow-8.29M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out3.91M

Employees9

ListedTue, Jan 11, 2022

Free float10.13M

Float %96.5%

Short interest26.24K

Days to cover0.8d

Short volume24.8%

Squeeze score4 / 100

Next earningsThu, Aug 6, 2026 (42d)

EPS forecast−$0.83 · 2 est

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank32.7 / 100

Group rank—

Status laneNo active setup

Setup direction—

Pattern family

Resistance1.11

Support0.9133

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in REVB

All disclosures →

No recent disclosed trades by Congress in REVB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in REVB · 2 sells

Insider	Side	Shares	Value	Traded	Filed
Zygmont Chester Stanley III Chief Financial Officer · Common Stock · 2026-04-30	Other	—	—	2026-04-30	2026-05-01
Rolke James Chief Executive Officer · Common Stock · 2026-04-30	Tax	10.12K	$11K	2026-04-30	2026-05-01
Zygmont Chester Stanley III Chief Financial Officer · Common Stock · 2026-04-30	Tax	13.29K	$15K	2026-04-30	2026-05-01

SEC filings

EDGAR filings in REVB · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.